Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of basic fuchsin in tumor resistance, and drug

An anti-tumor and fuchsin technology, applied in the field of tumor treatment, can solve problems such as drug resistance

Active Publication Date: 2020-08-07
QIQIHAR MEDICAL UNIVERSITY
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, like other antineoplastic drugs, disease progression and drug resistance inevitably occur after long-term use of EGFR-TK1, and most patients develop drug resistance after 8-10 months of medication

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of basic fuchsin in tumor resistance, and drug
  • Application of basic fuchsin in tumor resistance, and drug
  • Application of basic fuchsin in tumor resistance, and drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] From January 2013 to December 2018, patients with lung adenocarcinoma diagnosed by histology or cytology were collected from the Clinical Pathological Diagnosis Center of Qiqihar Medical College, and 61 patients who met the inclusion criteria of the research group's research plan were selected from them. The patient's clinical information mainly includes: age, gender, smoking history, ECOG score, tumor TNM stage, EGFR mutation status, EGFR-TKI usage, toxic and side effects during treatment, and curative effect evaluation after treatment, etc.

[0053] Case inclusion criteria: EGFR sensitive mutation mainly refers to Exon19 deletion or Exon21L858R mutation; pathological diagnosis is lung adenocarcinoma; clinical stage is III b and IV; meets Jackman's clinical criteria, and has received first-line EGFR-TKI treatment failure and secondary resistance Drug-resistant patients; EGFRT790M wild-type gene test, ECOG score 0-2 points; tumor lesions can be measured, such as CT scan ...

Embodiment 2

[0063] Effect of basic fuchsin on the proliferation inhibition rate of human lung adenocarcinoma cells

[0064] method:

[0065] (1) Preparation of basic fuchsin

[0066] Weigh an appropriate amount of the standard product basic fuchsin, dissolve it in a 0.1% ethanol solution, prepare a mother liquor with an appropriate concentration, and store it at 4°C for later use. Dilute to the desired concentration with complete medium during experiments.

[0067] (2) Preparation of Gefitinib

[0068] Take flake gefitinib, grind it in a mortar, dissolve it in dimethyl sulfoxide (DMSO), filter it through a 0.22 μm sterile filter, and make a gefitinib mother solution with a suitable concentration, store it at -20°C Save for later. When used, thaw and prepare the required concentration with complete medium.

[0069] (3) Preparation of complete medium

[0070] Fetal bovine serum was stored at -20°C and thawed overnight in a refrigerator at 4°C before use. When preparing complete medium,...

Embodiment 3

[0087] Effects of basic fuchsin on the sensitivity of PC9 / GR cells to gefitinib

[0088] (1) Gefitinib (10 μM) combined with different concentrations of basic fuchsin was used to act on the cells for 48 hours, and the cell proliferation inhibition rate was detected by MTT method, and it was judged that different concentrations of basic fuchsin were sensitive to gefitinib in PC9 / GR cells Sexual effects (see Table 5 and Figure 5 ).

[0089] Cells in the logarithmic growth phase were selected, and the control concentration was 5×10 4 cells / mL, 200 μL / well was inoculated in a 96-well plate, and placed at 37°C and 5% CO 2 12h in the incubator. After the cells adhered to the wall, the medium was changed, and basic fuchsin with a concentration of 0.5 μmol / L, 1.0 μmol / L, 1.5 μmol / L, 2.0 μmol / L, and 2.5 μmol / L was added, and 20 μm gefitinib was added at the same time. 200 μl medium of Nitrate. Design 4 parallel wells for each concentration, select 0.1% DMSO as the negative contro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of basic fuchsin in tumor resistance, and a drug, and relates to the technical field of tumor treatment. The invention discloses application of basic fuchsin in preparation of an antitumor drug. The tumor is a tumor with positive EGFR expression. It is found for the first time that basic fuchsin can significantly improve the life quality of patients with advanced lung adenocarcinoma and prolong the lifetime, meanwhile, proliferation of human lung adenocarcinoma cells can be inhibited, mRNA expression of PI3K, Akt and mTOR can be reduced, protein expression of p-PI3K, p-Akt and p-mTOR can be weakened, and it is prompted that the basic fuchsin can be used for treating tumors such as tumors with positive EGFR expression. The invention provides a new treatment method, a new strategy and a new thought for preventing and treating tumors with positive EGFR expression, especially tumors with drug resistance after being treated by an epidermal growth factor receptor tyrosine kinase inhibitor.

Description

technical field [0001] The invention relates to the technical field of tumor treatment, in particular to the application and medicine of basic fuchsin in antitumor. Background technique [0002] Lung cancer is the malignant tumor with the highest morbidity and mortality in my country, and 85% of lung cancer is non-small cell lung cancer (non-small cell lung cancer, non-small cell lung cancer, NSCLC). Non-small cell lung cancer includes adenocarcinoma, squamous cell carcinoma, and large cell lung cancer, and lung adenocarcinoma is the most common and common subtype. Most patients with lung adenocarcinoma present as locally advanced or distant metastatic disease that is refractory to surgery and / or radiotherapy, so systemic chemotherapy and / or targeted therapy are the main treatments. However, due to various reasons, some patients develop drug resistance, which reduces the effect of chemotherapy, leading to disease progression, recurrence or distant metastasis. Almost all lun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/136A61P35/00
CPCA61K31/136A61P35/00
Inventor 董海影李洪杰石寒冰高子寒
Owner QIQIHAR MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com